Angiogenesis in cervical cancer is mediated by HeLa metabolites through endothelial cell tissue kallikrein

Oncology Reports

Volumn 22, Issue 2, 2009, Pages 285-293

  Naidoo, Strinivasen ^a   Raidoo, Deshandra Munsamy ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Angiogenesis; Cervical cancer; HeLa; Tissue kallikrein

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SERINE PROTEINASE; TISSUE KALLIKREIN;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METABOLITE; MITOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER;

CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; TISSUE KALLIKREINS; UTERINE CERVICAL NEOPLASMS;

EID: 68349112399     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000436     Document Type: Article

References (51)

1. Garcia A: Cervical cancer. The Medscape Journal http://www.emedicine.com/ MED/topic324.html, 16 October, 2008.
2. Hockel S, Schlenger K, Vaupel P and Hockel M: Association between host tissue vascularity and the prognostically relevant tumor vascularity in human cervical cancer. Int J Oncol 19: 827-832, 2001.
3. Phoophitphong T, Hanprasertpong J, Dechsukhum C and Geater A: Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection. J Obstet Gynaecol Res 33: 840-848, 2007.
4. Wiggins DL, Granai CO, Steinhoff MM and Calabresi P: Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol 56: 353-356, 1995.
5. Cooper RA, West CM, Wilks DP, Logue JP, Davidson SE, Roberts SA and Hunter RD: Tumour vascularity is a significant prognostic factor for cervix carcinoma treated with radiotherapy: independence from tumour radiosensitivity. Br J Cancer 81: 354-358, 1999.
6. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL and Dirix LY: Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2474-2484, 1996.
7. Hlatky L, Hahnfeldt P and Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893, 2002.
8. Kisker O, Onizuka S, Becker C, Fannon M, Flynn E, D'Amato R, Zetter B, Folkman J, Ray R, Swamy N and Pirie-Shephard S: Vitamin D binding protein-macrophage activating factor (DBFmaf) inhibits angiogenesis and tumor growth. Neoplasia 5: 32-40, 2003.
9. Gargett CE, Bucak K and Rogers PAW: Isolation, characterization and long-term culture of human myometrial microvascular endothelial cells. Hum Reprod 15: 293-301, 2000.
10. Bischoff J: Cell adhesion and angiogenesis. J Clin Invest 99: 373-376, 1997.
11. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP and Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157: 2329-2333, 1997.
12. Ferrara N: Vascular endothelium growth factor. Eur J Cancer 32A: 2413-2422, 1996.
13. Fidler IJ: Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87: 1588-1592, 1995.
14. Kodama J, Seki N, Tokumo K, Hongo A, Miyagi Y, Yoshinouchi M, Okuda H and Kudo T: Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 35: 485-489, 1999.
15. Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M and Kamura T: Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett 264: 36-43, 2008.
16. Ueda M, Terai Y, Yamashita Y, Kumagai K, Ueki K, Yamaguchi H, Akise D, Hung YC and Ueki M: Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 98: 335-343, 2002.
17. Pietras K, Pahler J, Bergers G and Hanahan D: Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5: e19, 2008.
18. Emanueli C, Zacheo A, Minasi A, Chao J, Chao L, Salis M, Stacca T, Straino S, Capogrossi M and Madeddu P: Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol 20: 2379-2385, 2000.
19. Naidoo S, Raidoo D, Mahabeer R and McLean M: Tumour metabolites regulate tissue kallikrein in human umbilical vein endothelial cells. Biochim Biophys Acta 1691: 117-127, 2004.
20. Yayama K, Kunimatsu N, Teranishi Y, Takano M and Okamoto H: Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta 1593: 231-238, 2003.
21. Desrivieres S, Lu H, Peyri N, Soria C, Legrand Y and Menashi S: Activation of the 92 kDa type IV collagenase by tissue kallikrein. J Cell Physiol 157: 587-593, 1993.
22. Saksela O: Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 823: 35-65, 1985.
23. Koshikawa N, Yasumitsu H, Umeda M and Miyazaki K: Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res 52: 5046-5053, 1992.
24. Dlamini Z, Raidoo DM and Bhoola KD: Tissue kallikrein and kinin receptors in oesophageal carcinoma. Immunopharmacology 43: 303-310, 1999.
25. Hermann A, Buchinger P and Rehbock J: Visualisation of tissue kallikrein in human breast carcinoma by two-dimensional western blotting and immunohistochemistry. Biol Chem Hoppe Seyler 376: 365-370, 1995.
26. Farmer SG: The Kinin System. Academic Press Inc., San Diego, 1997.
27. Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, Testa AC, Werner U, Navarra P, Tringali G, Battaglia A and Scambia G: Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 9: 4324-4331, 2003.
28. Young JL, Jazaeri AA, Darus CJ and Modesitt SC: Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 109: 140-145, 2008.
29. Mazibrada J, Ritta M, Mondini M, De Andrea M, Azzimonti B, Borgogna C, Ciotti M, Orlando A, Surico N, Chiusa L, Landolfo S and Gariglio M: Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol 108: 112-120, 2008.
30. Spiryda LB and Colman DR: Suppression of tumorigenicity in an aggressive cervical carcinoma induced by protein zero, a nervous system IgCAM. J Cell Sci 111: 3253-3260, 1998.
31. Kemme M, Podlich D, Raidoo D, Snyman C, Naidoo S and Bhoola K: Identification of immunoreactive tissue prokallikrein on the surface membrane of human neutrophils. J Biol Chem 380: 1321-1328, 1999.
32. Bhoola KD, Elson CJ and Dieppe PA: Kinins - key mediators in inflammatory arthritis. Br J Rheumatol 31: 509-518, 1992.
33. Bhoola R, Ramsaroop R, Naidoo S, Muller-Esterl W and Bhoola KD: Kinin receptor status in normal and inflammed gastric mucosa. Immunopharmacol 36: 161-165, 1997.
34. Naidoo S, Ramsaroop R, Bhoola R and Bhoola K: The evaluation of tissue kallikrein in Helicobacter pylori-associated gastric ulcer disease. Immunopharmacology 36: 263-269, 1997.
35. Schacter M: Kallikreins (kininogenases) - A group of serine proteases with bioregulatory actions. Pharmacol Rev 31: 1-17, 1980.
36. Altman D: Practical Statistics for Medical Research. Chapman and Hall, London, 1991.
37. Obiezu CV and Diamandis EP: Human tissue kallikrein gene family: applications in cancer. Cancer Lett 224: 1-22, 2005.
38. Clements JA: The molecular biology of kallikreins and their roles in inflammation. In: The Kinin System. Farmer SG (ed). Academic Press Inc., San Diego, CA, pp71-98, 1997.
39. Matsumura Y, Maruo K, Kimura M, Yamamoto T, Konno T and Maeda H: Kinin-generating cascade in an advanced cancer patient: an in vitro study. Jpn J Cancer Res 82: 732-741, 1991.
40. Raidoo D, Sawant S, Mahabeer R and Bhoola KD: Kinin receptors are expressed in human astrocytic tumour cells. Immunopharmacology 43: 255-263, 1999.
41. Rehbock J, Buchinger P, Hermann A and Figueroa C: Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas. J Cancer Res Clin Oncol 121: 64-68, 1995.
42. Shaw JL and Diamandis EP: A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology. Biol Chem 389: 681-688, 2008.
43. Rixon RH and Whitfield JF: Kininogenases, kallikrein. Schattauer-Verlag, Stuttgart, 1973.
44. Bhoola KD, Figueroa CD and Worthy K: Bioregulation of kinins: Kallikreins, kininogens and kininases. Pharmacol Rev 44: 1-80, 1992.
45. Chao J, Stallone JN, Liang Y-M, Chen L-M, Wang D-Z and Chao L: Kallistatin is a potent new vasodilator. J Clin Invest 100: 11-17, 2000.
46. Chao J, Tillman DM, Wang MY, Margolius HS and Chao L: Identification of a new tissue - kallikrein-binding protein. Biochem J 239: 325-331, 1986.
47. Shih Ie M, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Muller-Holzner E, Gastl G, Zhang Z and Diamandis EP: Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 105: 501-507, 2007.
48. Guo P, Xu L, Pan S, Brekken R, Yang S-T, Whitaker G, Nagane M, Thorpe P, Rosenbaum J, Huang H-J, Cavanee WK and Cheng S-Y: Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res 61: 8569-8577, 2001.
49. Stadnicki A, Chao J, Stadnicki I, van Tol E, Lin K-F, Li F, Sartor B and Colman RW: Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats. Am J Physiol 275: G854-G861, 1998.
50. Stadnicki A, Mazurek U, Gonciarz M, Plewka D, Nowaczyk G, Orchel J, Pastucha E, Plewka A, Wilczok T and Colman RW: Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease. Dig Dis Sci 48: 615-623, 2003.
51. Naidoo S: The role of tissue kallikrein in Helicobacter pylori-associated gastric disease. Clinical and Experimental Pharmacology, University of Natal Medical School, University of Natal Library, Durban, p203, 1999.